Background: High-dose chemotherapy with autologous stemcell transplantation is used increasingly in the treatment of poor-prognosis primary breast cancer. Because these patients may be cured with standard multimodality therapy, it is important to address both the efficacy of transplantation, and its effect on the delivery of standard treatments including local radiation therapy.
Introduction
In North America, breast cancer has become the most common indication for high-dose chemotherapy with autologous stem-cell support [1] . Cure is unlikely once metastatic disease is established, and patients with early stage disease who are at high risk for recurrence are treated aggressively with adjuvant systemic therapy. Unfortunately, among patients with four or more involved axillary lymph nodes, an unacceptably high percentage of individuals will relapse despite conventional adjuvant therapy [2] [3] [4] . Reports of the use of high-dose chemotherapy regimens with autologous bone marrow or peripheral stem-cell support for high-risk patients have been encouraging, but inconclusive [5] [6] [7] . Currently, several randomized-controlled trials of high dose chemotherapy versus standard dose chemotherapy are nearing completion, and will assess the relative efficacy of each approach. While the precise role of high-dose therapy for breast cancer remains to be determined, stem-cell transplant continues to be widely implemented in high-risk patients with stage II and III breast cancer. A significant percentage of these patients may be cured of their disease with surgery, radiation therapy and conventional-dose systemic therapy. Potential longterm toxicities of the high-dose approach and its interaction with the delivery of standard aspects of treatment must be addressed. In particular, a major concern has been that delay in the administration of radiation, when it is deferred until after transplantation, might compromise local-regional control of disease.
In this analysis, we report the outcome of over 100 consecutive high-risk breast cancer patients treated on a single protocol at the Hospital of the University of Pennsylvania with high dose cyclophosphamide and thiotepa and stem cell support. Survival and diseasefree survival were determined. The ability to administer adjuvant local-regional radiation therapy in these patients and the pattern of initial sites of failure in the context of these findings are presented. Additionally, long-term toxicities including cardiac toxicity, delayed hematologic recovery, and the incidence of second malignancies were studied.
Patients and methods

Patient population
From June 1992 to December 1997, 107 women with high-risk breast cancer were treated with high-dose chemotherapy and stem-cell transplant. A minimum potential follow-up period of four months from transplant was required for this analysis. Prior to September 1995, patients were required to have stage II or Ilia breast cancer with involvement of 10 or more axillary lymph nodes. In September 1995, an amendment to the protocol extended eligibility to patients with four to nine involved lymph nodes. Women between the ages of 18 and 66 were eligible and all cases of breast cancer were histologically confirmed. Local-regional therapy prior to transplant consisted of either modified radical mastectomy or lumpectomy with axillary dissection. Local-regional radiation therapy prior to transplant was permitted but not required. Patients with clinical, radiographic, or pathologic evidence of metastatic breast cancer were excluded. Screening for metastatic disease included chest X-ray, liver function testing, CT scan of the abdomen and pelvis and bilateral bone marrow biopsies and aspirates. Adequate organ function was required and included an absolute neutrophil count 3=1500/ul, platelets > 100,000/ul, bone marrow cellulanty ^ 30%, cardiac ejection fraction > 45%, creatimne clearance of >60 cc/min or serum creatinine <1.5, bilirubin 2 mg/dl, and AST and alkaline phosphatase < 2 times the upper limit of normal. Written informed consent was obtained from all patients according to the guidelines of the Institutional Review Board of the University of Pennsylvania.
Treatment
Prior to enrollment, patients underwent conventional dose adjuvant chemotherapy Patients enrolled before September 1995 underwent bone marrow harvest as well as peripheral stem cell harvest prior to transplant. After determination of eligibility and enrollment, a minimum of 2 x 10 8 nucleated cells/kg were harvested from the bone marrow by multiple aspirations from the posterior iliac crest under general, spinal, or epidural anesthesia. The harvested bone marrow cells were cryopreserved in 10% DMSO at a concentration of 2 x 10 7 cells/ml using a controlled rate freezer and were stored in liquid nitrogen at -196 °C. Patients then underwent colony stimulating factor (CSF) stimulated peripheral stem cell harvest. Patients received GM-CSF 250 ug/kg or G-CSF 10 ug/kg subcutaneously daily for eight days. Peripheral blood mononuclear cells were collected via a doublelumen subclavian pheresis catheter using a cell separator by four-hour continuous flow leukopheresis for a total of three collections on approximately days 4, 6 and 8 of CSF. The protocol was amended in September 1995 so that subsequent patients underwent peripheral stem cell harvest without bone marrow harvest. These patients were mobilized with G-CSF 10 ug/kg subcutaneously daily and underwent collection every other day until 6 x 10 8 mononuclear cells/kg were harvested. Peripheral stem cells were resuspended in 10% DMSO and autologous plasma and cryopreserved in 100 ml bags in a controlled rate freezer and stored at -196 °C.
The high-dose chemotherapy regimen consisted of cyclophosphamide 1500 mg/m 2 as a continuous infusion daily for four days and thiotepa 200 mg/m 2 as a continuous infusion daily for four days. The calculation of body surface area was based on ideal body weight or actual weight, whichever was less. Cryopreserved bone marrow and/or peripheral stem cells were thawed and infused via a central venous catheter at least 48 hours after completion of chemotherapy. GM-CSF 250 ug/kg or G-CSF 5 ug/kg was administered subcutaneously from the day of stem cell infusion until an absolute neutrophil count greater than 1000/ul had been maintained for 48 hours.
Supportive measures during the transplant included the routine administration of irradiated blood and random donor platelet products for hemoglobin levels less than 8.0 g/dl and for platelet counts less than 20,000/ul. With the first fever 3= 100.5 "F during neutropenia, broadspectrum antibiotics were administered until the ANC reached 500/ul.
Patients received routine prophylaxis against oral thrush with appropriate antifungals.
Patients with positive estrogen and/or progesterone receptors were treated with tamoxifen 20 mg/day following hematopoetic recovery. Patients who did not receive local-regional radiation prior to transplantation received radiation treatment to the breast or chest wall and to ipsilateral axillary and supraclavicular lymphatics after hematopoetic recovery. The suggested technical delivery of post-mastectomy and post-breast conservation radiotherapy was as previously described [8, 9] ,
Endpoints
Patients were evaluated for survival and disease-free survival from the day of stem-cell or bone marrow infusion. For all calculations involving dates, the exact date of the event was used whenever possible. When a date was only known to the nearest month, the first day of that month was used. Sites of first relapse were determined. Recurrences in the ipsilateral breast, chest-wall, axilla or supraclavicular region were categorized as local-regional failures. The incidence of second malignancies was also assessed. Information about local and systemic therapy preceding the transplant was obtained and included type of surgery received, whether or not local-regional radiation therapy was administered prior to transplant and total doxorubicin exposure prior to transplant. The number of CD34+ stem cells infused at the time of transplant and the source of these cells (bone marrow vs peripheral stem cells plus bone marrow) were recorded. Hematopoetic parameters included time to neutrophil engraftment (ANC > 500/ul), platelet engraftment (day of platelet count of >20,000/ul after last platelet transfusion and last platelet count ^ 20,000/ul), platelet recovery (platelet count > 100,000/ul) and time to self-sustaining Hgb > 8 g/dl. Cardiac toxicity was assessed by serial cardiac MUGA scans. The change in ejection fraction was determined both from the pre-transplant evaluation and from screening MUGA scans obtained prior to anthracychne-containing induction therapy. In calculating doxorubicin doses, actual doses (per square meter) were used whenever available. In cases where actual doses were not available, standard doses for a given regimen were assumed (e.g., 60 mg/m 2 per cycle of AC). Reported radiation doses are the minimum total dose to the tumor bed for breast conservation patients and to the chest wall for mastectomy patients as documented in radiation therapy records.
Statistical analysis
Descriptive statistics (median, minimum, maximum, frequency, percentage and 95% CI) were employed to describe the patient factors and harvest products (numbers of CD34+ cells reinfused). Survival was defined as days from reinfusion to death due to any cause or last patient contact, while disease-free survival was defined as days from reinfusion to documented recurrence, death due to any cause or last patient contact. The Kaplan-Meier method [10] was employed to estimate survival and disease-free survival rates. The Kaplan-Meier method was employed to estimate time to hematologic (absolute neutrophil count, platelet or hemoglobin) recovery. Patients alive and yet to experience engraftment were censored at last contact. Patients who died without recovery were censored after the longest observed recovery time. Percent change in ejection fraction from pre-to posttransplant and from pre-induction to post-transplant were calculated by the formula, [(pre-post/pre) x 100], Group comparisons were performed by chi-square test for categorical factors, f-test for continuous factors and log-rank test [11] for survival and disease-free survival. Excluding patients who died without recovery, Spearman's correlation coefficient Rho (p) was employed to assess the magnitude of linear association between time to hematologic recovery and total number of CD34+ cells infused. Statistical analyses were performed with SPSS for Windows software (SPSS Inc. Chicago, IL). All cited P-values are two-sided. 
# (%)
24 (24) 53 (54) 22 (22) 21 (20) 20 (19) 84 (82) 63 (61) 51 (50) Results
Patient characteristics
Of the 107 patients enrolled, 2 were excluded from the analysis for failure to meet eligibility criteria. One patient had known stage IV disease prior to transplant by virtue of involvement of a supraclavicular lymph node. A second patient, who had received neoadjuvant chemotherapy, had pathologic involvement of only one axillary lymph node. Two additional patients were not evaluable and therefore excluded from this analysis. One patient was lost to follow-up after moving out of state within four months of the transplant and therefore did not meet the follow-up requirement for this analysis. A second patient was inevaluable because no outpatient records could be located. The remaining 103 patients are included in this report. The patient population is described in Table 1 . In two cases of bilateral breast cancer, characteristics of the higher risk tumor are reported for this analysis. The median age at transplantation was 45 (range 24-62). Eighty-two patients (79.6%) had a mastectomy and 20 (19.4%) had lumpectomy plus axillary dissection for the primary tumor. One patient, with an axillary presentation, had no identifiable primary and surgical treatment consisted of axillary dissection only. The median size of the primary tumor was 2.8 cm (range 0.5-9.4 cm), with a median of 14 (range 4-42) involved axillary lymph nodes. Eighty-four patients (81.6%) had involvement of 10 or more axillary lymph nodes. Forty-five patients (43.7%) were ER and PR positive, eighteen (17.5%) were ER positive only, six (5.8%) were PR positive only, and thirty-four (33.0%) were ER and PR negative. For all but one patient standard induction chemotherapy prior to transplantation included a doxorubicin-based regimen 16 (20) 44 (54) 21 (26) 66 (80) 17 (20) 50 (60) 38 (46) with a median total doxorubicin dose of 300 mg/m 2 (range 233-480 mg/m 2 ). The regimens used were variations of CAF (n = 51), AC alone (n = 41), combinations of doxorubicin-based chemotherapy plus CMF (n = 6), combinations of doxorubicin-based chemotherapy and a taxane (n = 3) and CMF alone (n = 1). The median time from diagnosis to transplant was approximately 34 weeks (range 16-77 weeks). Twenty patients (19.4%) had received local-regional radiation therapy prior to transplant. The characteristics of these patients were similar to the rest of the series in terms of age and type of surgery ( Table 2 ). The group with up-front radiation tended to have smaller tumors (P = 0.06) and, although not statistically significant, they had a somewhat higher incidence of over 10 lymph nodes involved and tumors that were more frequently progesterone receptor positive.
Stem-cell and bone marrow collection and infusion
Thirty patients received both peripheral stem cells and bone marrow while seventy-three patients received peripheral stem cells only. The total number of mononuclear cells harvested per kilogram per patient was a median of 8. ) per kilogram in patients receiving both bone marrow and stem cells.
Survival and progression-free survival
The median potential follow-up is 19.0 months for the entire cohort of patients and 17.3 months (range 4.1-64.5 months) for patients alive at last follow-up. The overall survival and disease-free survival rates (±SE) at 18 months were 83% (± 4%) and 77% (± 4%) respectively (a) Overall Survival
Time to Recurrence Months Figure I . Kaplan-Meier estimate of survival (a) and disease-free survival (b) for 103 patients from day of transplant. At 18 months overall survival is 83% (± 4%) and disease-free survival is 78% (± 4%).
( Figures la and b) . Four patients (3.9%) died from acute toxicity related to the transplant procedure. No deaths were seen from causes other than transplant toxicity or disease progression during the follow-up period. The median overall survival time has not yet been reached. The median disease-free survival time is 52.6 months. Risk of distant relapse appears to continue over the observation period, as noted in Figure 2 .
Initial sites of relapse
Of twenty-seven patients with recurrence, 26 had documentation of the initial site of relapse. The most common site of initial recurrence was bone (nine patients), followed by lung (seven patients) and local-regional failure (six patients, Table 3 ). The central nervous system was the first site of relapse for only one patient. On average, local-regional failures occurred earlier (median of 5.9, range 2.0-27.9 months) than distant failures (median 10.2, range 1.7-52.6 months). 
Hematopoetic toxicity and engraftment
The median time to engraftment of neutrophils (absolute neutrophil count >500/ul) was 10 days (range 9-29). Patients were transfusion independent at a median of 9 days for red blood cells (range 2-840+ days) and 33 days for platelets (range 7-126 days). Excluding patients who died within the first 100 days (toxic deaths), 10 patients failed to reach a platelet count of greater than 100,000/|il. Two of these patients died of progressive disease at 6.7 and 31.2 months. The remaining eight are alive with platelet counts ranging from 19,000/ul to 91,000/ul at follow-up intervals ranging from 8.7 to 44.4 months. Neutrophil and platelet engraftment were more prolonged in patients receiving both marrow and peripheral blood stem cells compared with patients receiving stem cells alone (data not shown). This finding is confounded, however, by the use of GM-CSF rather than G-CSF in many of the earlier patients receiving bone marrow and peripheral stem cells, as well as by a lower median number of CD34+ cells infused in the patients receiving bone marrow and peripheral blood stem cells. There were highly significant correlations between the number of CD34+ cells infused and time to engraftment. Higher number of CD34+ cells infused was associated with shorter time to neutrophil engraftment (p = -0.66, P < 0.001), shorter time to platelet engraftment (p = -0.38, P -0.001), and shorter time to platelet recovery (p = -0.52, P < 0.001). No correlation was seen between the total number of mononuclear cells infused and engraftment measures.
Cardiac toxicity
The median ejection fraction as determined by cardiac MUGA scan in 100 patients prior to transplant, but following induction chemotherapy, was 60% (range 45%-88%). Post-transplant, the median ejection fraction for 67 evaluable patients was 57%. The median percent change in EF was a 4.9% decline from baseline (SD 13.4%). Sixty-two percent of 66 evaluable patients with a post-transplant MUGA scan experienced a decline in ejection fraction relative to the pre-transplant evaluation. A greater than 20% decline from the pre-transplant ejection fraction was observed in only 4.5% of 66 evaluated patients.
For 51 patients, results of MUGA scans prior to anthracycline-containing induction chemotherapy were available and compared with post-transplant ejection fractions. The median percent change was a 10.5% decline from baseline (SD 14.4%) over the entire systemic chemotherapy course (induction plus transplant). Despite anthracycline-based induction therapy and high-dose chemotherapy, 97% of patients evaluated in this series had an ejection fraction of greater than 45% after completion of the transplant.
Second malignancies
Two second malignancies were observed. One patient, with a family history of breast and brain tumors, developed a malignant ependymoma at seven months following the transplant. At 18 months post-transplant she was alive and disease-free following surgical resection and brain irradiation. A second patient was diagnosed with non-Hodgkin's lymphoma at 54 months following transplant; this coincided with a diagnosis of breast cancer recurrence. The pre-transplant bone marrow biopsy of this patient was notable for the presence of suspicious lymphoid cells, but a diagnosis of lymphoma was not confirmed at that time. No cases of myelodysplasia or AML have been observed in this cohort.
Radiation therapy
Twenty patients (19.4%) received radiation therapy prior to transplant. Of the remaining 83 patients, excluding 2 who died during transplant, all but 4 (95.1%) were able to receive radiation therapy to the affected breast or chest wall and regional lymph nodes. Treatment doses were available for 11 of 20 patients irradiated before transplant and for 65 of 77 patients irradiated after transplant. The median dose of radiation administered to patients receiving delayed radiation therapy was 5040 cGy (range 3060-6680 cGy) which was similar to the median dose of 5000 cGy (range 4500-6500 cGy) administered to patients treated prior to transplantation. Only one evaluated patient received a dose of less than 4500 cGy. Radiation was completed a median of 43 weeks (range 26-76 weeks) after definitive surgery in patients irradiated after transplant while patients receiving radiation therapy prior to transplant completed local therapy in a median of 35 weeks (range 11-50 weeks). Of the patients receiving radiation therapy after transplant, 79.2% completed this therapy within a year of surgery. For the four patients who were unable to get local-regional radiation therapy, the reasons were prolonged thrombocytopenia (three patients) and disease progression (one patient). The patient who progressed prior to radiation therapy had a local (supraclavicular) recurrence as her first documented site of relapse. Of the three patients who were unable to get radiation therapy because of thrombocytopenia, two were alive and disease-free at approximately 23 and 31 months, while one patient died of progressive systemic disease at approximately 7 months.
In the entire series, 5 of 26 known sites of first recurrences (19.2%) were local-regional alone. For patients receiving radiation prior to transplant, three of seven first recurrences (43%, 95% CI: 6%-80%) were local-regional, while patients in whom radiation was deferred until after transplant (including those who were unable to receive radiation therapy) 2 of 19 first recurrences (10.5%, 95% CI: 0%-24.5%) were localregional only (Table 4) . Disease-free survival appeared similar in patients who did or did not receive localregional radiation prior to transplant (Figure 3) .
When site of first recurrence was evaluated in terms of the number of weeks to completion of local radiation therapy, regardless of timing in relation to transplantation, no significant association was observed between a longer interval to completion of radiation therapy and site of first recurrence (P -0.47). Among 27 patients completing radiation therapy within 36 weeks of definitive surgery, 1 recurrence was local alone, 1 was concurrent local and distant recurrence and 7 were distant recurrences alone. Seventy patients had an interval of greater than 36 weeks to completion of radiation therapy and in this group, 3 recurrences were local alone while 12 were distant alone. 
Disease-free Survival
Prognostic factors
The extent of axillary lymph node involvement did not predict for outcome as survival appeared similar in patients with four to nine involved lymph nodes and those with > 10 involved lymph nodes. Similarly, patients with tumors measuring < 2.0 cm, 2.0-5.0 cm and > 5.0 cm did not have a significant difference in disease-free or overall survival. Estrogen receptor-positivity and progesterone receptor-positivity were significantly associated with improved survival and disease-free survival (data not shown). Patients in the 4 to 9 positive lymph node group were predominantly ER negative (58%) and PR negative (79%) while patients with 10 or more involved lymph nodes were predominantly ER positive (66%) and PR positive (56%). The distribution of estrogen receptor and progesterone receptor positivity was similar among the three different size categories of tumors with respective frequencies of 62.5% and 41.7% for tumors < 2 cm, 64.2% and 58.5% for tumors 2.0-5.0 cm and 50.0% and 36.4% for tumors > 5 cm.
Discussion
We report a large consecutive series of high-risk breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation at a single institution. Treatment-related mortality was lower than described for similar patients in earlier reports [5] . We have not, however, confirmed a plateau in the diseasefree survival, with distant recurrences presenting more than two years after transplantation. Although our median follow-up is relatively short, disease-free survival curves appear to approximate those of similar patients reported to the National Bone Marrow Registry [1] . While this phase II trial cannot directly compare the efficacy of a high-dose therapy approach to that of standard dose chemotherapy alone, it offers important observations regarding toxicity and the impact of autologous stem cell transplant on our delivery of standard multimodality therapies. With current use of CSF's and stem cells, we have seen rapid hematologic recovery which correlated significantly with higher numbers of CD34+ cells infused. Prolonged thrombocytopenia is an important factor in the timing of administration of local-regional radiation therapy, but resulted in omission of radiation therapy in only two patients.
The issue of delaying radiation therapy has become of particular importance in light of recent data suggesting that prevention of local relapses may reduce subsequent development of metastatic disease. In 1997, two large randomized trials of post-mastectomy radiation therapy in conjunction with systemic chemotherapy [12, 13] reported not only a significant decrease in local-regional recurrence rates, but a survival advantage in patients receiving post-mastectomy radiation over mastectomy and chemotherapy alone. While there may be concern that the delay in the completion of local-regional therapy which occurs in patients undergoing transplant may be detrimental, it is also conceivable that high-dose chemotherapy contributes importantly to local control. We have investigated this issue by determining our ability to deliver full doses of radiation therapy, the timing of this therapy and the proportion of first relapses which occurred locally.
There was some variability in the dosing and technique of radiation therapy in this series as a substantial proportion of patients received radiation treatment in their local community rather than at the center where transplantation was performed. It was recommended, however, that patients receive a total cumulative dose of 5000 cGy delivered, using a 6 MV linear accelerator, to the affected breast or chest wall as well as ipsilateral supraclavicular and axillary lymphatics in 25 fractions. Boosts to the tumor bed were frequently incorporated. Radiation of the internal mammary nodes was not recommended. No formal assessment of compliance to these guidelines was performed.
It has been suggested that an adequate dose of adjuvant local radiation therapy for breast cancer is 4400 cGy or more [14] . In this series, most patients were able to receive adequate doses of radiation therapy regardless of timing in relation to transplantation. Despite delaying radiation until after transplant in the majority of patients, there did not appear to be an unexpectedly high proportion of local-regional failure relative to distant failure, suggesting that high-dose chemotherapy may enhance rather than interfere with local control. Marks et al. have observed that three of nine high-risk breast cancer patients receiving high-dose chemotherapy without local-regional radiation developed local-regional failure within one year of the t/:.nsplant [14] . In the current series, delayed radiation Lvapy was not associated with an increase in the percentage of first failures which were local, even with th~ _ ..-.Ion of non-irradiated patients in the delayed gr.-;.
• vnce patients were not randomized as to the timing of the radiation therapy it is difficult to draw conclusions from differences in the two groups. It is possible that patients who were at particularly high risk for local-regional failure might have preferentially been treated with radiation therapy prior to transplant. Our data suggest that the population receiving early irradiation was not at significantly higher risk for local-regional failure. While this group had a somewhat higher incidence of ten or more lymph nodes involved, the patients generally had smaller tumors and were more likely to be hormone receptor positive. The frequency of breast-conserving surgery was similar in the two groups.
While local-regional failure rates in other adjuvant studies of high-risk breast cancer patients are of interest, varying follow-up periods and differences in patient populations make cross-study comparisons of failure rates difficult. The percentage of first sites of failure which are local-regional, however, may serve as a relative measure of the adequacy of local-regional control. In the National Surgical Adjuvant Breast Project (NSABP) study B-04, approximately 24% of first recurrences were local-regional in patients with clinically positive axillary lymph nodes who were randomized to simple mastectomy plus radiation. In more recent trials, in which patients have received systemic chemotherapy in addition to post-operative radiation, the relative frequency of local-regional site of first relapse is somewhat lower [12, 13] . In patients randomized to post-mastectomy radiation therapy in conjunction with chemotherapy in the Canadian and Danish studies, 20.2% and 12.2% of respective first relapses were local-regional alone. In the patients randomized to standard chemotherapy without radiation in these trials, 44.6% and 28% of first relapses were local-regional. Despite breast-conserving surgery in approximately 20% of the patients in the current series, the observed relative frequencies of local-regional site of first relapse in this series (19.2% overall and 10.5% for patients in whom XRT was delayed or omitted) are comparable to the frequencies observed with aggressive local therapy in other studies. In addition, the relatively short follow-up period in the current study may overestimate the relative frequency of local-regional recurrence given that local-regional relapse tended to occur earlier than distant failure in this and other studies [15, 16] .
It has previously been suggested that local failure rates are increased relative to distant recurrences when local-regional radiation therapy is delivered after rather than before a standard 12-week course of adjuvant chemotherapy in patients undergoing breast-conserving surgery [17] . Leonard et al. also investigated the effect of timing of radiation therapy on the pattern of recurrence [18] . In their report, patients received predominantly CMF chemotherapy and the interval from definitive surgery to radiation ranged from less than one month to greater than six months. Delaying radiation for chemotherapy did not result in an increase in local failure rates. In the current series we have similarly found the clinical implications of delaying local-regional radiation therapy for transplantation to be minor if any.
Cardiac function after stem cell transplantation when preceded by anthracycline-based induction regimens has also been assessed. We found that the cardiac toxicities of transplant were acceptable in terms of the ability to effectively deliver standard chemotherapy. While we did observe a decline in cardiac ejection fraction, the degree of cardiac toxicity attributable to the transplant procedure was not greater than that attributable to doxorubicin use in this series. Furthermore, the overall decline following both anthracycline-containing induction therapy and high dose therapy was modest, with 97% of patients maintaining a cardiac ejection fraction above the level that was used as an eligibility criterion for enrollment.
The potential for induction of second malignancies represents another long-term concern for patients receiving high-dose chemotherapy. The two second malignancies seen in this series were an ependymoma in a patient with a family history consistent with a familial cancer syndrome and a low grade lymphoma. These appear unlikely to have been a result of transplantation, but it is not clear how transplantation, and the associated immunosuppression, affected the natural history of these second malignancies in terms of either timing of presentation or progression. Secondary myelodysplasia and acute leukemia are felt to be uncommonly associated with autologous bone marrow transplant for breast cancer [19] and have not been observed in this series. The incidence of second malignancies may increase with longer follow-up.
In addition to an evaluation of transplant toxicities, this analysis addresses the value of known prognostic indicators in the setting of bone marrow transplantation. The degree of lymph node involvement and tumor size appear to lose significance as prognostic factors in this selected high-risk population. Disease-free survival curves are similar for the 4 to 9 and the 10 or more positive lymph node groups. Referral bias may explain the failure of patients with 4 to 9 involved lymph nodes to achieve a superior outcome to patients with involvement of 10 or more nodes. For instance, patients with four to nine involved lymph nodes were more likely to be hormone receptor negative; a higher perceived risk of recurrence may have influenced the decision to refer this group of patients for transplant. The size of the primary tumor was not associated with outcome after transplant and may have less prognostic significance in this population with multiple involved lymph nodes receiving peripheral stem cell transplant.
Despite aggressive cytotoxic chemotherapy, hormone receptor status remains an important predictor of outcome for these high-risk patients. Somlo et al. also found that ER and PR positivity were associated with a superior outcome with transplantation [20] . These findings underscore the importance of standard adjuvant hormonal therapy even in conjunction with high-dose chemotherapy and transplantation.
As the role of transplantation in breast cancer evolves, it is important to continue to assess the interactions of high-dose chemotherapy and conventional aspects of therapy. Adequate cardiac function was generally maintained after transplantation even with prior anthracycline-based induction chemotherapy. We have seen that local-regional radiation therapy can be administered in full doses to the majority of patients. Even when radiation therapy was delayed until after transplantation, an acceptable relative rate of local-regional failure was observed. In this series of high-risk breast cancer patients we have found that treatment with high-dose cyclophosphamide and thiotepa followed by autologous stem-cell transplantation can be administered without significant compromise in the delivery of standard therapy.
